PSMA-PET/CT imaging provides highly accurate information for the initial staging of newly diagnosed prostate cancer patients.1 However, it is crucial to recognize the causes of PSMA uptake in non-prostatic diseases to ensure treatment planning accuracy and avoid misinterpretation. The gene discussed is FOLH1; the disease is prostate carcinoma.